Shining light on women's health.™
Redefining the standard of care for both yeast & bacterial vaginal infections.
A prescription medical device platform that delivers controlled, visible-spectrum, microbicidal light. No hormones. No systemic drugs. A fundamentally different mechanism.
A Smarter Way to Treat Infection
A new standard in treating yeast &
bacterial infections.
Cern Corporation is advancing a prescription medical device that uses controlled, visible spectrum light to safely and effectively treat both yeast and bacterial vaginal infections without hormones or systemic drugs. A fundamentally different mechanism that holds significant promise.
Antimicrobial Resistance
Helping reduce antimicrobial resistance by decreasing antibiotic use.
Drug-Free Treatment
Addressing both yeast & bacterial infection without the use of drugs.
Birthrate & Fertility
Supporting reproductive health by addressing bacterial vaginosis.
Remote Health
Expanding access through remote women's health solutions.
The Unmet Need
A Common Condition. An Ongoing Challenge. Millions of Women Are Affected.
Vaginal infections affect hundreds of millions of women globally. The standard treatments antibiotics and antifungals leave most patients in a vicious spiral of growing drug resistance, microbiome disruption, and recurrence.
Fungal Vaginitis / Yeast
Fungal Vaginitis / Yeast
BV and
Birthrate
BV impacts both conception and pregnancies
Many women who are recurrent, may suffer both yeast and bacterial infections simultaneously. Cern’s treatment uniquely addresses both.
The Science
A targeted, natural approach to vaginal infection.
Cern’s platform delivers low-level, visible-spectrum, microbicidal light directly to infected vaginal tissue. This is not UV light, but a precisely selected wavelength designed to interact with pathogens through a well-characterized, non-pharmacologic mechanism. The CernDevice™ is designed to work with our proprietary photosensitizing, lubricating gel which both enhances and reduces the duration of treatment.
Based on controlled dosing, Cern’s platform has the ability to selectively address pathogenic organisms while enabling preservation of key beneficial microbes, which may exhibit greater resilience to treatment. This distinction may be particularly important for women experiencing recurrent infections. Pre-clinical data demonstrate greater than 99.999% reduction of key yeast and bacterial pathogens, including drug-resistant strains.
Our Team
Science built for women.
Cern was founded with a clear mission: to create a safe, effective, non-drug alternative for the millions of women for whom drug based therapies are neither effective, appropriate or desired. At the core of our development is an exceptional team of clinicians, engineers, and researchers — bringing together urogynecology, microbiology, medical device engineering, and decades of combined scientific leadership. This is not a problem we are observing from the outside. It is one we are committed to solving.
Cern’s technology is grounded in well-established scientific principles and leverages mechanisms that are widely understood and accepted within the scientific community. Its innovation lies in applying these proven concepts to address a significant clinical problem from an entirely new perspective, offering a novel, non-drug approach to treatment.
Melanie Santos, MD
Chief Medical Officer
Urogynecology & Pelvic Reconstructive Surgery specialist with over 17 years of experience.
Hyunsook Park, PhD
Director, Microbiology
Microbiology professor with 20+ years of research experience in fungal pathogenesis.
News & Updates